Peeling Back The Layers: Exploring Macrogenics Through Analyst …

Nov 7, 2024 · The perception of Macrogenics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and …

$85.33
OFF

Peeling Back The Layers: Exploring Carrier Global Through Analyst ...

4 weeks from now

Dec 5, 2024 · Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $85.33, with a high estimate of $94.00 and a low estimate of $76.00.

nasdaq.com

$34.92
OFF

Peeling Back The Layers: Exploring Range Resources Through …

4 weeks from now

Nov 18, 2024 · In the assessment of 12-month price targets, analysts unveil insights for Range Resources, presenting an average target of $34.92, a high estimate of $45.00, and a low …

benzinga.com

$84
OFF

Peeling Back The Layers: Exploring Coastal Finl Through Analyst …

4 weeks from now

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $84.0, a high estimate of $96.00, and a low estimate of $73.00. This …

webull.hk

$93.62
OFF

Peeling Back The Layers: Exploring MetLife Through Analyst

4 weeks from now

Nov 27, 2024 · The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $93.62, a high estimate of $99.00, and a low estimate of $90.00.

nasdaq.com

$23.09
OFF

Peeling Back The Layers: Exploring Kinder Morgan Through …

4 weeks from now

Oct 11, 2024 · The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $23.09, a high estimate of $27.00, and a low estimate of $21.00.

benzinga.com

FAQs about Peeling Back The Layers: Exploring Macrogenics Through Analyst … Coupon?

How do analysts evaluate MP Materials?

This insight gives a snapshot of analysts' perspectives on the current state of the company. Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MP Materials compared to the broader market. ...

Why did MacroGenics stock rise 110% in premarket trade?

Visit a quote page and your recently viewed tickers will be displayed here. Shares of biotech MacroGenics Inc. shot up 110% in premarket trade Wednesday after the company announced that the Phase 3 trial of potential breast cancer treatment margetuximab met its primary endpoint. Margetuximab is t... ...

Is MacroGenics a biopharmaceutical company?

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. ...